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Oral versus intravenous clarithromycin in
moderate to severe community-acquired
pneumonia: an observational study
Nikolas Rae1, Aran Singanayagam2, Stuart Schembri1 and James D. Chalmers1*
Abstract
Objectives: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam antibiotics for
patients with community-acquired pneumonia and CURB-65 score 2–5. Intravenous therapy is commonly used but
there are few data on whether oral therapy is equally effective.
Methods: This observational study used propensity matching to compare two groups of patients with moderate to
severe community-acquired pneumonia (CURB-65 score 2–5) treated with oral (n = 226) or intravenous (n = 226)
clarithromycin on admission. Outcomes were 30-day mortality, intensive care unit admission, time to clinical
stability, and length of hospital stay.
Results: There was no significant difference in 30-day mortality (16.8% for intravenous [IV] group vs. 14.6% for oral
group, hazard ratio for IV group 1.11 95% CI 0.70–1.78), ICU admission (10.6% in both groups) or complications
(10.6% for IV group and 9.3% for oral group) between the groups. The time to clinical stability in both cohorts
was a median of 5 days (interquartile range 3–7 days, p = 0.3). The median length of hospital stay was 8 days in
the IV group (interquartile range 4–14 days) and 7 days in the oral group (interquartile range 4–13 days), p = 0.5.
No other differences were observed between oral and IV groups.
Conclusion: Where the oral route is not compromised, oral macrolides appear to be equivalent to IV in treating
moderate to severe CAP.
Keywords: Macrolide, Pneumonia, Severity, Combination therapy, Antibiotic
Introduction
Guidelines for treatment of community-acquired
pneumonia (CAP) recommend adding an intravenous
(IV) macrolide to a β-lactam agent (penicillin, penicil-
lin/β-lactamase inhibitor combination or second/third
generation cephalosporin) in the treatment of moder-
ate to severe CAP [1, 2]. There is currently no evi-
dence that the route of administration of macrolides
alters clinical outcome.
Macrolides are commonly used in the management of
respiratory tract infections, with particular activity
against atypical organisms in addition to Streptococcus
pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis [3, 4]. Oral clarithromycin has a bioavailabil-
ity of approximately 55% and excellent pulmonary tissue
penetration, achieving concentrations higher than those
observed in plasma [5, 6]. Peak plasma concentrations
are achieved within 2 h [6]. IV administration is more
expensive and may be associated with a higher rate of
adverse effects, thus administration by the oral route
is preferable wherever possible [7, 8]. Recent random-
ized controlled trials have given conflicting data on
the overall value of macrolides in the management of
community-acquired pneumonia [9, 10]. A non-inferiority
trial from Switzerland [9] comparing β-lactam monother-
apy to β-lactam plus macrolide concluded that β-lactam
monotherapy was not non-inferior in terms of time to
clinical stability. A significant difference suggesting that
macrolides improve rate of clinical recovery was demon-
strated, driven by a higher effectiveness in a small group
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of patients with atypical pathogens [9]. In contrast, a clus-
ter randomized controlled trial in The Netherlands [10]
has recently reported no benefit in terms of mortality for
hospitals randomized to a regime consisting of β-lactam
plus macrolide, compared to β-lactams alone. None of
these studies have addressed whether macrolides should
be administered orally or intravenously. A recent study
[11] has examined the administration of fluoroquinolones
and concluded that administration of fluroquinolones or-
ally was at least equivalent to IV administration in CAP
patients.
The aim of this study was to ascertain if the route of
administration of macrolides was associated with out-
come in patients with moderate or severe community-
acquired pneumonia.
Methods
This study was a secondary analysis of a prospectively
collected database (2005–2009) that has been described
previously. Data collection was approved by the South
East Scotland Research Ethics Committee (reference
numbers S1104/15 and S1103/27).
Inclusion and exclusion criteria
Patients were included in the study if they presented
with new infiltrates on chest radiograph along with signs
and symptoms suggestive of pneumonia [12]. In
addition, patients were eligible for inclusion in the
present analysis if they had a CURB-65 score of between
2 and 5 and received an IV β-lactam with clarithromycin
(either IV or oral) as the initial antibiotic treatment regi-
men on admission, as per British Thoracic Society (BTS)
guidelines [2].
Exclusion criteria were hospital-acquired pneumonia,
active malignancy, immunosuppression, pulmonary em-
bolism, tuberculosis, and patients in whom active treat-
ment was not considered appropriate. In addition, for
this analysis patients were excluded if the oral route
was compromised or if they received a non-guideline
concordant antibiotic regime.
Propensity matching
The probability that a patient would receive oral or IV
clarithromycin was assessed with multivariable logistic
regression to create a propensity score [13]. The vari-
ables included in the propensity model were all of
those available to clinicians at admission (symptoms,
demographics, co-morbidities, clinical variables, la-
boratory results and radiology). Each patient treated
with IV ß-lactam and oral clarithromycin was then
matched to a patient treated with IV ß-lactam and IV
clarithromycin with a similar propensity score, using
greedy matching. This created two cohorts that were
well matched for measured confounders. As a sensitivity
analysis to exclude strong differential effects among pa-
tients that could not be matched, the analysis was also re-
peated including the propensity score as a covariate in the
Cox proportional hazards regression [14].
The group who received initial IV β-lactam with IV
clarithromycin are referred to in the manuscript as the
IV group, and those who initially received IV β-lactam
with oral clarithromycin are referred to as the oral
group.
Outcomes
The primary outcome was 30-day mortality, with sec-
ondary outcomes including length of hospital stay, in-
tensive care unit (ICU) admission and development of
empyema or complicated parapneumonic effusion.
Statistical analyses
Statistical analyses were performed using SPSS version
21 (IBM, New York, United States). Propensity matching
was performed using the propensity matching add-on
for SPSS (SPSS essentials for R and R version 2.14.2).
The propensity analysis is described above. Between the
treatment groups, outcomes were assessed after multi-
variable adjustment using Cox proportional hazards
regression. The multivariable analysis included age,
gender and CURB-65 score. More extensive models in-
cluding all variables in Table 1 were also tested to re-
duce unmeasured confounding. A sensitivity analysis
was performed in patients with CURB-65 scores 3–5,
as this group are recommended for IV macrolides in
the BTS guidelines [2].
Results
Patients
There were 1,113 patients who had a CURB-65 score
2–5 and were eligible for inclusion in the study. Of
these, 761 patients received guideline concordant ther-
apy consisting of a ß-lactam and a macrolide. There
were 118 patients with a compromised oral route that
were excluded (all had IV therapy). The final cohort for
matching consisted of 226 patients in the oral clarithro-
mycin group and 417 patients treated with IV clarithro-
mycin. The dose administered was not recorded but
local guidelines recommended 500mg twice daily for
both oral and IV administration.
Propensity matching
In the logistic regression analysis, IV therapy was not in-
dependently associated with any of the variables consid-
ered; the strongest relationship was with oral antibiotic
therapy prior to admission (odds ratio for IV therapy,
1.67 95% CI 0.96–2.92) (Table 1).
There were no patients in the oral group that could
not be matched and, therefore, 452 patients were
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included after propensity matching, with 226 patients in
the IV group propensity matched to 226 patients in the
oral group. There were no significant differences in
demographics, or physiological or laboratory parameters
between the two groups, as shown in Table 2.
Outcomes: propensity matched cohort
There were 38 deaths (16.8%) in the IV group and 33
deaths (14.6%) in the oral group (p = 0.5). There was no
significant difference in 30-day mortality of multivariable
analysis (hazard ratio [HR] for IV group 1.11 95% CI
0.70–1.78). The time to clinical stability was a median of
5 days in both cohorts (interquartile range [IQR] 3–7
days, p = 0.3).
There were 24 patients (10.6%) who were admitted to
the ICU >24 h after admission in both groups (p = 1.0)
with no differences between the groups evident in multi-
variable analysis (HR 1.07 95% CI 0.72–1.59). There
were 24 patients (10.6%) who developed empyema or
complicated parapneumonic effusion in the IV group
compared to 21 (9.3%) in the oral group (p = 0.6) with
no difference between the groups on multivariable ana-
lysis (HR 1.06 95% CI 0.59–1.91). The median length of
hospital stay was 8 days in the IV group (IQR 4–14 days)
and 7 days in the oral group (IQR 4–13 days), p = 0.5.
Figure 1 shows a Kaplan-Meier curve of 30-day mortal-
ity for the two groups.
In the analysis limited to patients with CURB-65 scores
3–5 (n = 272), the hazard ratio for mortality was 1.16
(0.67–2.03) and for ICU admission was 1.14 (0.73–1.78).
Outcomes: sensitivity analysis
To exclude strong confounding effects from patients ex-
cluded from the propensity analysis, we performed a
Cox proportional hazard regression including all patients
Table 1 Multivariable analysis of factors associated with
intravenous macrolide treatment
Variable Odds ratio (95% CI), p-value
Gender (male) 0.79 (0.55–1.13), p = 0.2
Age 1.01 (0.99–1.03), p = 0.1
Congestive cardiac failure 0.83 (0.51–1.35), p = 0.5
Liver disease 0.94 (0.44–2.00), p = 0.9
Stroke 1.23 (0.68–2.22), p = 0.5
COPD 0.80 (0.52–1.23), p = 0.3
Diabetes 1.06 (0.63–1.80), p = 0.8
Smoking status 1.04 (0.71–1.52), p = 0.8
CURB-65 score 1.13 (0.90–1.41), p = 0.3
Temperature 1.07 (0.89–1.29), p = 0.5
Pulse rate 1.0 (0.99–1.01), p = 0.4
Prior statin use 1.11 (0.71–1.75), p = 0.7
Antiplatelets 1.01 (0.65–1.56), p = 0.9
ACE inhibitors/ARBs 0.90 (0.56–1.45), p = 0.7
Beta-lactam co-administration 0.89 (0.56–1.41), p = 0.6
Corticosteroid use 0.90 (0.49–1.66), p = 0.7
Sodium level 0.99 (0.95–1.03), p = 0.5
Haemoglobin 1.00 (0.99–1.01), p = 0.4
White cell count 1.01 (0.99–1.02), p = 0.3
Platelet count 1.00 (0.99–1.00), p = 0.8
Albumin 1.0 (0.49–1.66), p = 0.7
Multilobar radiographic changes 1.14 (0.73–1.79), p = 0.6
Antibiotic treatment prior to admission 1.67 95% CI 0.96–2.92), p = 0.08
COPD chronic obstructive pulmonary disease, ACE inhibitors, angiotensin-
converting-enzyme inhibitors, ARBs, angiotensin receptor blockers
Table 2 Characteristics of the IV and oral clarithromycin groups
after propensity matching
Characteristics IV macrolide Oral macrolide p-value
N 226 226
Age 71 (59–78) 71 (62–79) 0.5
Gender 116 (51.3%) 121 (53.5%) 0.6
Confusion 40 (17.7%) 41 (18.1%) 0.9
Respiratory rate 30 (20–32) 30 (20–33) 0.7
SBP 108 (91–129) 108 (90–130) 0.9
Temperature 38 (37–38.4) 38 (37–38.4) 0.9
Pulse 105 (90–120) 105 (90–120) 0.7
H+ 38 (34–43.7) 38 (34–43) 0.4
Urea 8.2 (6.4–11.7) 8.5 (6.7–11.9) 0.4
Sodium 136 (133–138) 136 (133–138) 0.8
Glucose 6.6 (5.7–8.0) 6.9 (5.7–8.5) 0.2
CRP 231 (102–339) 209 (94–352) 0.7
WCC 15.3 (11.5–20.0) 15.1 (10.1–19.4) 0.6
Albumin 36 (32–39) 36 (33–40) 0.5
CURB-65 3 (2–3) 3 (2–3) 0.1
Data are median IQR except gender, which is presented as n (%)
SBP systolic blood pressure, CRP C-reactive protein, WCC, white cell count,
IV intravenous, IQR interquartile range
Fig. 1 Kaplan-Meier plot of 30-day mortality between patients
receiving oral or intravenous clarithromycin for moderate to
severe community-acquired pneumonia
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(n = 643) considered for inclusion in the propensity ana-
lysis. In this analysis, the hazard ratios were similar to
the primary analysis: 30-day mortality HR for IV therapy
was 1.14 (95% CI 0.74–1.76); 30-day mortality HR for
ICU admission was 1.16 (95% CI 0.83–1.62) and 30-day
mortality HR for complicated pneumonia was 1.18 (95%
0.71–1.98), compared to oral therapy.
Discussion
The addition of an IV macrolide to a β-lactam agent in
the treatment of moderate or severe CAP is recom-
mended in national and international guidelines [1, 2].
This study indicates that in patients with moderate or
severe CAP where the oral route is not compromised,
treatment with oral clarithromycin is as effective as IV
clarithromycin when combined with an IV β-lactam.
Oral therapy has several theoretical advantages, includ-
ing reducing costs and risk of complications of IV ad-
ministration of drugs [15].
Macrolides are primarily added to provide cover for
atypical pathogens. Atypical pathogens are not associ-
ated with bacteraemia, and bacteraemia is the only cir-
cumstance where prompt IV antibiotic therapy is shown
to give a mortality benefit [16]. Clarithromycin has a
high bioavailability and achieves a peak serum concen-
tration 2 h following oral administration [5]. The highly
lipophilic nature of macrolides result in excellent tissue
penetration irrespective of route of administration, with
clarithromycin achieving concentrations up to 20 times
greater in pulmonary epithelial tissues than in serum.
Since IV clarithromycin is typically administered over 1
h, the difference in time to reach peak serum concentra-
tions is highly unlikely to be clinically relevant.
In the UK, IV clarithromycin is at least 10 times more
expensive than oral clarithromycin [17]. This cost does
not include the time required for preparation of IV med-
ications or consumables used for IV administration of
drugs. CAP is common and even relatively small in-
creases in the use of oral clarithromycin would result in
significant cost savings.
There has been an ongoing debate about the relative
value of macrolides in the management of CAP [9, 10].
Although some observational studies suggest a mortality
benefit with macrolide containing regimes, a meta-
analysis of observational studies could not conclude a
definite benefit associated with macrolides in CAP [18]
and a Cochrane review of randomized controlled trials
(primarily of fluroquinolones) have failed to demonstrate
a benefit for giving empirical atypical coverage in CAP
[19]. Macrolides are now known to be associated with
significant adverse effects including the induction of
antibiotic resistance and Clostridium difficile [20–23].
Macrolides have been linked with cardiovascular events,
although this association is controversial [24, 25]. While
attention has focused on the potential for macrolides to
prolong the QT interval or destabilize atherosclerotic
plaques, a more simple explanation for some of the re-
ported events is the large volume IV infusions required
to administer. The question of the clinical value of
macrolides will not be resolved without definitive ran-
domized controlled trials. Two randomized trials have
recently evaluated this question but have given some-
what conflicting results. Garin et al [9] could not dem-
onstrate non-inferiority of ß-lactam alone compared to
combination therapy with a primary outcome of time to
clinical stability. This is not the same as saying that
macrolide therapy speeds up clinical recovery, but this
was certainly the case for a subgroup of patients with
atypical infection in this study [9]. Larger studies would
be needed to evaluate if macrolide indeed result in more
rapid clinical response. Postma et al [10] reported a clus-
ter randomized trial in The Netherlands where hospitals
were randomized to a strategy consisting of ß-lactam
plus macrolide, ß-lactam alone or fluoroquinolone. The
study found that hospitals had similar mortality rates re-
gardless of the strategy used, with no mortality benefit
for macrolides demonstrated [10]. Limitations of the
study included the cluster design that allowed significant
deviations from the assigned antibiotic regime and a
population of patients with predominantly mild disease.
Therefore, while awaiting a definitive answer to the
question of which patients benefit from macrolide ther-
apy, it is possible to minimise the harm associated with
macrolides by following guideline recommendations for
these agents, using the shortest duration necessary and,
as this study shows, some harms and costs may be mini-
mized by using oral therapy in preference to IV
administration.
Limitations of this study must be acknowledged. This
is an observational study, and although the oral and IV
groups were well matched after excluding patients too
severely ill to take oral medications, unmeasured con-
founding may remain. A randomized controlled trial
would be required for confirmation. This study is the
largest to address this question, but would be underpow-
ered to detect small differences in outcome between the
groups. Sample size was determined based on the avail-
able data. Nevertheless, it must be noted that none of
the hazard ratios suggested a harmful effect of oral
therapy.
Conclusion
This observational study suggests that route of adminis-
tration of clarithromycin in patients with moderate or
severe CAP is not associated with a difference in clinical
outcome, in patients able to take oral therapy. This
would justify a definitive randomized controlled trial.
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